Expertscape, a web platform that used the PubMed database and its patented algorithm to identify and objectively rank physicians and researchers that excel in the treatment and diagnosis of specific disease states, has released their rankings for U.S. physicians who specialize in the research and treatment of colorectal cancer. Using Expertscape’s rigorous process, Douglas Rex, M.D.,…
In response to the rising incidence of CRC in patients younger than 50 years, the USPSTF proposes CRC screening at 45 years as the new clinical standard.
This fact sheet discusses the rising incidence of colorectal cancer among young adults.
A cross-sectional survey of patients with CRC revealed a lack of nutritional advice, as well as awareness of its availability.
A retrospective study sought to determine the accuracy of the GNRI in predicting postoperative complications and overall survival in elderly patients with colorectal cancer.
A meta-analysis of randomized controlled trials found that there are significant risks for severe or fatal adverse events with ramucirumab, with only modest improvements in OS or PFS.
The FDA has approved Keytruda (pembrolizumab; Merck), a programmed death receptor-1 -blocking antibody, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Researchers assessed whether adherence to oral antidiabetic medication was a modifiable prognostic factor in patients with CRC and preexisting diabetes.
Although some tumors lack aneuploidy or have few extra chromosomal copies, others have a slew of mutations.
All patients enrolled in the phase 3 study had metastatic CRC characterized as MSI-H/dMMR, a biomarker found in only approximately 5% of these tumors.
